Sangamo Biosciences (SGMO) Reports FDA Acceptance of IND for SB-BCLmR-HSPC; Will Initiate Phase 1/2
Tweet Send to a Friend
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
